Navigation Links
Edison expands North American healthcare sector coverage with initiation of coverage on Alexza Pharmaceuticals
Date:8/28/2013

LONDON, Aug. 28, 2013 /PRNewswire/ -- Edison has recently published a comprehensive report examining the investment merits of Alexza Pharmaceuticals, which are largely based on the company's lead asset, Adasuve (Staccato loxapine), approved in the US and the EU for the acute treatment of agitation in adults with bipolar disorder or schizophrenia. In the report, All eyes on Adasuve, Edison healthcare analyst, Pooya Hemami, argues that Alexza's investment case is underpinned by Adasuve's ability to provide a rapid therapeutic response in a non-invasive formulation, offering a unique treatment option that does not require physicians to trade off either speed of effect or non-coercive dosing. Given the risk of physical injury or property damage with agitated patients in whom agitation is escalating, and that competing treatment options are either slow to act or invasive, Edison believes the advantages of quick effect and ease of administration will position Adasuve as a key agent for the initial treatment of acute agitation in medical emergency settings. Based on a risk-adjusted NPV analysis, Edison values Alexza at $85m, or $6.77 per share (fully diluted) inclusive of $32m in cash (30 June 2013).

For the full report see: http://www.edisoninvestmentresearch.com/research/company/alexza-pharmaceuticals

The launch of coverage on Alexza Pharmaceuticals is part of a programme of research initiations on healthcare companies worldwide. Edison provides research coverage on more than 130 healthcare companies in Europe, North America and Australia. Edison has pioneered a scientific, detail-oriented approach to analysing companies in the healthcare sector that is delivered in a concise and non-promotional manner. It aims to inform investors, while providing a realistic assessment of the competitive strengths and threats to key drug development programmes. All facts are carefully sourced and the analysis is underpinned by comprehensive and rigorous financial models. Edison's reports provide an overall company valuation without any specific stock recommendation.

All reports published by Edison are available to download free of charge from its website www.edisongroup.com.

About Edison Investment Research

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals works with leading companies, fund managers and investment banks worldwide to support its capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Berlin, Sydney and Wellington. Edison is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584).

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact:

Pooya Hemami  Edison Investment Research +1 514 475 2384

healthcare@edisongroup.com

About Alexza Pharmaceuticals

Alexza Pharmaceuticals is a US-based company developing products for acute central nervous system disorders using its proprietary Staccato aerosol rapid drug delivery system. Lead product, Adasuve, is approved in the US and EU for acute treatment of agitation in patients with schizophrenia or bipolar disorder. Teva Pharmaceuticals is Alexza's commercial partner for Adasuve in the US, and Grupo Ferrer Internacional, SA is Alexza's commercial partner for the product in Europe, Latin America, Russia and the Commonwealth of Independent States countries.


'/>"/>
SOURCE Edison Investment Research
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Diabecline Antibiotic Receives Edison Award for Best New Pharmaceutical Product
2. Carolinas HealthCare System and Edison Nation Collaborate to Drive Medical Innovation and Technology
3. EMA Grants Orphan Designation to Edison Pharmaceuticals for EPI-743 for Treatment of Leigh Syndrome
4. Edison Pharmaceuticals Announces Positive Results of EPI-743 Phase 2A Leigh Syndrome Clinical Trial
5. Massive Hiring Event for Life Science Professionals in Edison, NJ on 9/18/12
6. Edison Pharmaceuticals Announces Initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
7. Edison Pharmaceuticals Closes $20M Series F Financing
8. Samsung Medison Showcases New Medical Equipment and Technology with Samsung Electronics at RSNA 2012
9. Edison Pharmaceuticals & Bambino Gesu Childrens Hospital Announce Initiation of EPI-743 Phase 2 Cobalamin C Deficiency Syndrome Clinical Trial
10. Edison Pharmaceuticals, Inc. signs licensing agreement with Dainippon Sumitomo Pharma Co., Ltd. for development & commercialization of orphan mitochondrial and adult central nervous system disease drugs
11. Edison Expands North American Healthcare Sector Coverage With Initiation of Coverage on Bellus Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... 2017  True Health, a leader in integrated ... during National Breast Cancer Awareness month to educate ... Research recently published ... more than 10 million American women are at ... or BRCA2 and have not had testing. These mutations ...
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/7/2017)... --  Provista, a proven leader in the supply ... power, today announced a new resource area on Provistaco.com ... is the online home for case studies, articles on ... releases, slideshows and events. ... at their fingertips, viewers can also watch short videos ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 13, 2017 , ... Lori R. Somekh, founder of the Law Office ... of elder law and special needs planning attorneys. “Membership in ElderCounsel helps our office ... forum to network with elder law attorneys nationwide,” said Somekh. , ElderCounsel ...
(Date:10/13/2017)... ... ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out many kids this ... by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting kids excited about ... ages; it is a non-competitive, non-timed event, which is all about having fun and ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “America On The ... identity. “America On The Brink” is the creation of published author, William Nowers. ... great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), ... of an innovative new design of the shoulder pad. The shoulder pad provides ... while controlling your pain while using cold therapy. By utilizing ice and water that ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a ... of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners ... October 11, 2017. , The annual award competition recognizes editorial and design excellence across ...
Breaking Medicine News(10 mins):